Gero

Gero is an Aging Drug Discovery company founded in 2018 and based in Singapore, Singapore.

Founded in 2018 by physicist Peter Fedichev (CEO) and Maxim Kholin, Gero is a Singapore-based company with a San Francisco subsidiary that builds a 'physics-first' AI platform for aging. Drawing on statistical-physics and dynamical-systems theory, plus AI models trained on large human datasets, Gero distinguishes reversible disease states from irreversible aging to nominate therapeutic targets. The company partnered with Pfizer in a 2023 research collaboration on fibrotic-disease targets, and in July 2025 signed a joint research and license agreement with Roche's Chugai Pharmaceutical worth up to $250M in potential milestones and royalties for antibody therapies against age-related diseases. Gero was named a World Economic Forum 2026 Technology Pioneer.

Its physics-of-aging modeling won validation from two major pharma partners (Pfizer, Chugai), a rare external endorsement of computational aging-target discovery.

gero.ai Aging Drug Discovery

Singaporeprivate

At a glance

Total raised

Undisclosed

no public funding on record

Headcount

11-50

approximate · public range

Headquarters

Singapore

Founded

2018

8 years active

Status

Private

Aging Drug Discovery

Subsector

Funding history

Total raised

—

Rounds tracked

Latest stage

Series A extension

Date	Stage	Amount	Valuation	Lead investors
Oct 1, 2023	Series A extension	$6M	—	—

Gero

At a glance

Funding history

In the news

Gero raises $34M to advance physics-first aging medicines

Gero raises $17m to model the mathematics of aging

Watch

Leadership

Products

Physics-of-aging AI platform

Pharma target-discovery partnerships

Compare Gero with